Reporting owner · CIK 0001346824
Ra Capital Management, L.P.
Visual SEC Form 4 history across 10 companies, 41 transactions and 12 filings.
DIRArtiva Biotherapeutics, Inc.
Open-market mix
100%buys
Open-market buy performance
90-day forward return on this insider's open-market purchases
For every open-market buy (Form 4 code P, acquisition A) in the selected window, we take the closing price on the transaction date and 90 calendar days later, then compute the percentage change. The figures shown are the simple average and median of those per-buy returns.
- Window follows the rest of the summary (all-history or last 3 months).
- Only buys with a resolved price context are counted.
- Includes both positive and negative outcomes; gains and losses net out at the per-buy level.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
Jan 25
$50M
Feb 25
$35.2M
Mar 25
$25.3M
Jan 26
$24.9K
Feb 26
$59M
Jun 26
$0
Aug 26
$0
Sep 26
$0
Transaction texture
Ownership and ticket size
Average P/S size$15.4M
Median P/S size$9.3M
Direct0
Indirect41
Sep 08, 2026grant
Filing-only signals
Deterministic matches in this insider's history
Latest Form 4 facts
Quick context from source filings
Latest transaction
buy at SpyGlass Pharma, Inc. on Feb 09, 2026 valued at $3,968,544.
Review SEC filingLatest sale
No open-market insider sale is available.
Associated companies
Visual map of known reporting history
ARTVArtiva Biotherapeutics, Inc.1 transactions · latest Sep 08, 2026, 10:29 PMVORVor Biopharma Inc.2 transactions · latest Aug 26, 2026, 10:28 PMABOSAcumen Pharmaceuticals, Inc.2 transactions · latest Jun 05, 2026, 09:12 PMSGPSpyGlass Pharma, Inc.11 transactions · latest Feb 11, 2026, 10:15 PMCLYMClimb Bio, Inc.1 transactions · latest Jan 07, 2026, 09:55 PMJANXJanux Therapeutics, Inc.4 transactions · latest Mar 07, 2025, 11:05 PMMLYSMineralys Therapeutics, Inc.1 transactions · latest Feb 25, 2025, 02:41 AMSLDBSolid Biosciences Inc.1 transactions · latest Feb 21, 2025, 09:11 PMSIONSionna Therapeutics, Inc.16 transactions · latest Feb 10, 2025, 10:04 PMETNB89bio, Inc.2 transactions · latest Feb 05, 2025, 11:02 PM
| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| SION | RA CAPITAL MANAGEMENT, L.P. | DIR | C | 138k | $0 | C | — | 02/10/2025 | 02/10/2025 | |
| SION | RA CAPITAL MANAGEMENT, L.P. | DIR | C | 319k | $0 | C | — | 02/10/2025 | 02/10/2025 | |
| SION | RA CAPITAL MANAGEMENT, L.P. | DIR | C | 819k | $0 | C | — | 02/10/2025 | 02/10/2025 | |
| SION | RA CAPITAL MANAGEMENT, L.P. | DIR | buy | 102k | $184M | P | — | 02/10/2025 | 02/10/2025 | |
| SION | RA CAPITAL MANAGEMENT, L.P. | DIR | buy | 1.02M | $1.84B | P | — | 02/10/2025 | 02/10/2025 | |
| SION | RA CAPITAL MANAGEMENT, L.P. | DIR | C | 179k | — | C | — | 02/10/2025 | 02/10/2025 | |
| SION | RA CAPITAL MANAGEMENT, L.P. | DIR | C | 2.22M | — | C | — | 02/10/2025 | 02/10/2025 | |
| SION | RA CAPITAL MANAGEMENT, L.P. | DIR | C | 527k | — | C | — | 02/10/2025 | 02/10/2025 | |
| SION | RA CAPITAL MANAGEMENT, L.P. | DIR | C | 5.02M | — | C | — | 02/10/2025 | 02/10/2025 | |
| ETNB | RA CAPITAL MANAGEMENT, L.P. | DIR | grant | 56.4k | $0 | A | — | 02/05/2025 | 02/03/2025 |
Ra Capital Management, L.P. Insider Activity FAQ
SEC Form 4 context
Who is Ra Capital Management, L.P.?
Ra Capital Management, L.P. is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001346824.
Which companies has Ra Capital Management, L.P. reported transactions for?
Artiva Biotherapeutics, Inc., Vor Biopharma Inc., Acumen Pharmaceuticals, Inc., SpyGlass Pharma, Inc., Climb Bio, Inc., Janux Therapeutics, Inc., Mineralys Therapeutics, Inc., Solid Biosciences Inc., Sionna Therapeutics, Inc., 89bio, Inc.
When was Ra Capital Management, L.P.'s latest insider buy?
buy at SpyGlass Pharma, Inc. on Feb 09, 2026 valued at $3,968,544.
When was Ra Capital Management, L.P.'s latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.